Search results for "1310"

showing 10 items of 13 documents

Post-prandial alterations in LDL size and subclasses in patients with growth hormone deficiency

2008

Abstract Objective Several studies have suggested that lipoproteins generated during the post-prandial phase are highly atherogenic, with modifications in low-density lipoproteins (LDL) size and density. In the present study we assessed post-prandial variations in LDL size and subclasses in patients with growth hormone deficiency (GHD). Design We studied in 12 hypopituitary patients with GHD and 10 healthy control subjects matched for gender, age and body mass index (BMI) post-prandial variations after a standardized meal consisting of 35% fat, 45% carbohydrate and 20% of protein (Clinutren Mix ® , Nestle) and containing calories corresponding to 1/3 of estimated basal metabolic rate. Blood…

AdultMalemedicine.medical_specialtyCalorieEndocrinology Diabetes and Metabolism10265 Clinic for Endocrinology and Diabetology610 Medicine & healthPilot ProjectsHypopituitarismSubclassGrowth hormone deficiencyEndocrinologyInternal medicinemedicineHumansLipoproteinGel electrophoresisMealbusiness.industryMiddle AgedCarbohydratePost-prandialPostprandial Periodmedicine.diseaseSmall dense LDL1310 EndocrinologyLipoproteins LDL2712 Endocrinology Diabetes and MetabolismEndocrinologyCase-Control StudiesGrowth HormoneBasal metabolic rateGrowth hormone deficiencyFemalelipids (amino acids peptides and proteins)businessBody mass indexGrowth Hormone & IGF Research
researchProduct

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

2020

Genome sequencing and gene-based therapies appear poised to advance the management of rare lipoprotein disorders and associated dyslipidaemias. However, in practice, underdiagnosis and undertreatment of these disorders are common, in large part due to interindividual variability in the genetic causes and phenotypic presentation of these conditions. To address these challenges, the European Atherosclerosis Society formed a task force to provide practical clinical guidance focusing on patients with extreme concentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol. The task force also recognises the scarcity of qua…

medicine.medical_specialtyRare dyslipidaemiaConsensusSettore MED/09 - Medicina InternaGenotypediagnosisEndocrinology Diabetes and MetabolismMEDLINE030209 endocrinology & metabolism610 Medicine & health03 medical and health sciences0302 clinical medicineEndocrinologyRare DiseasesGenotype540 ChemistryInternal Medicinemedicinegeneome sequencingHumansgeneticsGenetic Predisposition to DiseaseRare dyslipidemias; genetics; diagnosis; treatment030212 general & internal medicineDisease management (health)Intensive care medicineHealth policyDyslipidemias10038 Institute of Clinical Chemistrytreatmentbusiness.industryTask forcegene therapiesDisease ManagementAtherosclerosisPhenotype1310 EndocrinologyEurope2712 Endocrinology Diabetes and MetabolismPhenotype2724 Internal MedicinePractice Guidelines as TopicRare dyslipidemiasEuropean atherosclerosis societylipids (amino acids peptides and proteins)businessQuality information
researchProduct

New national and regional Annex I Habitat records: from #60 to #82

2023

New Italian data on the distribution of the Annex I Habitats are reported in this contribution. Specifically, 8 new occurrences in Natura 2000 sites are presented and 49 new cells are added in the EEA 10 km × 10 km reference grid. The new data refer to the Italian administrative regions of Campania, Calabria, Marche, Piedmont, Sardinia, Sicily, Tuscany and Umbria. Relevés and figures are provided as Supplementary material respectively 1 and 2.

2250*1240 1310 1420 2250* 3130 3220 3260 3270 3280 4090 6110* 6430 7210* 8210 91AA* 91B0 91E0* 92A0 92D0 933091AA*92D01310142091B03270328032607210*933031308210124032206430Settore BIO/03 - Botanica Ambientale E Applicata409091E0*6110*92A0
researchProduct

Hystoria de los hechos del ... Cardenal Don Gil de Albornoz Arçobispo de Toledo ... / escripta en latin ... traduzida en castellano por ... Antonio …

1566

Caplletres historiades i ornades

Albornoz Gil Álvarez Carrillo de Cardenal (1310-1367)
researchProduct

Recommendations on the diagnosis and management of Niemann-Pick disease type C

2009

Niemann-Pick disease type C (NP-C) is a lysosomal storage disease in which impaired intracellular lipid trafficking leads to excess storage of cholesterol and glycosphingolipids in the brain and other tissues. it is characterized clinically by a variety of progressive, disabling neurological symptoms including clumsiness, limb and gait ataxia, dysarthria, dysphagia and cognitive deterioration (dementia). Until recently, there has been no disease-modifying therapy available for NP-C, with treatment limited to supportive measures. In most countries, NP-C is managed through specialist centers, with non-specialist support provided locally. However, effective patient Support is hampered by the a…

Adultmedicine.medical_specialtyNeurology1303 BiochemistryAdolescentEndocrinology Diabetes and Metabolism610 Medicine & healthDiseaseBiochemistry03 medical and health sciencesDysarthriaYoung Adult0302 clinical medicineEndocrinology1311 GeneticsGeneticsLysosomal storage diseasemedicine1312 Molecular BiologyDementiaHumansMass ScreeningIntensive care medicineChildMolecular BiologyMass screening030304 developmental biology0303 health sciencesNiemann–Pick disease type Cbusiness.industryInfant NewbornInfantNiemann-Pick Disease Type CMiddle Agedmedicine.disease3. Good health1310 Endocrinology2712 Endocrinology Diabetes and Metabolism10036 Medical ClinicChild PreschoolPhysical therapyGait Ataxiamedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome

2009

Summary Objective  Small, dense low-density lipoproteins (LDL) are a feature of the metabolic syndrome (MS) but their predictive role still remains to be established. We performed a 2-year follow-up study in 124 subjects with MS (63 ± 6 years), as defined by the American Heart Association/National Heart, Lung and Blood Institute guidelines, to assess clinical and biochemical predictors of cerebro- and cardio-vascular events. Methods and results  Beyond traditional cardiovascular risk factors, we measured LDL size and subclasses by gradient gel electrophoresis. Clinical events were registered in the 25% of subjects. At univariate analysis subjects with events had increased prevalence of elev…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism10265 Clinic for Endocrinology and Diabetology610 Medicine & healthCerebroCoronary artery diseaseEndocrinologyPredictive Value of TestsRisk FactorsInternal medicinemedicineHumansFamily historyLow-density lipoproteins (LDL metabolic syndromeAgedMetabolic SyndromeUnivariate analysisbusiness.industryMiddle Agedmedicine.disease1310 EndocrinologyLipoproteins LDL2712 Endocrinology Diabetes and MetabolismEndocrinologymedicine.anatomical_structureSmall dense low-density lipoproteins cardio events cerebro-vascular events the metabolic syndromeCardiovascular DiseasesPredictive value of testsCirculatory systemFemaleMetabolic syndromebusinessBlood vesselFollow-Up Studies
researchProduct

Continuous subcutaneous Insulin infusion leads to immediate, table, and long-term changes in metabolic control

2008

Background:  Evaluations of continuous subcutaneous insulin infusion (CSII) usually focus on one pre- and one post-CSII measurement to assess metabolic therapy outcome. Aim:  Extending this research, the aim of the present study was to provide a more fine-grained analysis of achieved glycaemic control. Methods:  In 52 patients with type 1 diabetes (mean age of 37.85 years at CSII begin; s.d. ± 12.41), haemoglobin A1c (HbA1c) levels were assessed every 3 months over a period of 5 years (1 year before and 4 years after the introduction of CSII). Mixed models were utilized to describe changes in glycaemic control. Results:  The pre–post course showed that already in the first quarter, a statis…

mixed modelsAdultBlood GlucoseMalemedicine.medical_specialtyPediatricstype 1 diabetesEndocrinology Diabetes and MetabolismModels BiologicalDrug Administration ScheduleTimeHba1c levelEndocrinologyDiabetes mellitusInternal Medicinemedicinefollow upHumansHypoglycemic AgentsInsulinAge of OnsetGlycated HemoglobinType 1 diabetesHaemoglobin A1cbusiness.industry10093 Institute of PsychologyCSIIMean ageInfusion Pumps ImplantableMiddle AgedPrognosismedicine.diseaseSubcutaneous insulinSurgery1310 Endocrinologylong-term changes2712 Endocrinology Diabetes and MetabolismDiabetes Mellitus Type 1Treatment Outcome2724 Internal MedicineMetabolic control analysisFemalebusiness150 PsychologyFollow-Up StudiesMetabolic therapy
researchProduct

Issues with European guidelines for phenylketonuria

2017

medicine.medical_specialtybusiness.industryPhenylketonuriasEndocrinology Diabetes and MetabolismMEDLINE610 Medicine & health1310 Endocrinology03 medical and health sciences2712 Endocrinology Diabetes and Metabolism0302 clinical medicineEndocrinology10036 Medical Clinic2724 Internal MedicineFamily medicinePhenylketonuriasInternal MedicineMedicineHumans030212 general & internal medicinebusiness030217 neurology & neurosurgery
researchProduct

Miglustat in patients with Niemann-Pick disease Type C (NP-C): A multicenter observational retrospective cohort study

2009

Miglustat has been shown to stabilize disease progression in children, juveniles and adults with Niemann-Pick disease type C (NP-C), a rare genetic disorder characterized by progressive neurological deterioration. We report findings from a retrospective observational cohort study assessing the effects of miglustat on neurological disease progression in patients treated in the clinical practice setting. Data from all NP-C patients prescribed miglustat at 25 expert centers were evaluated using a disease disability scale. The scale analyzed four key parameters of neurological disease progression in NP-C (ambulation, manipulation, language, swallowing). Mean individual parameter scores and a co…

MalePediatricsmedicine.medical_specialty1-Deoxynojirimycin1303 BiochemistryAdolescentEndocrinology Diabetes and Metabolism610 Medicine & healthDiseaseBiochemistryCohort StudiesEndocrinology1311 GeneticsMiglustat1312 Molecular BiologyGeneticsHumansMedicineEnzyme InhibitorsChildMolecular BiologyRetrospective StudiesNiemann–Pick disease type Cbusiness.industryNiemann-Pick Disease Type CRetrospective cohort studymedicine.disease1310 EndocrinologyClinical trial2712 Endocrinology Diabetes and MetabolismTreatment Outcome10036 Medical ClinicCohortFemalebusinessNiemann–Pick diseaseCohort studymedicine.drugMolecular Genetics and Metabolism
researchProduct

Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndrome…

2008

Somatostatin-producing neuroendocrine tumors (SOM-NETs) of the duodenum and pancreas appear to be heterogeneous. To determine their clinicopathological profiles, respective data were analyzed on a series of 82 duodenal and 541 pancreatic NETs. In addition, the clinical records of 821 patients with duodenal or pancreatic NETs were reviewed for evidence of a somatostatinoma syndrome. Predominant or exclusive expression of somatostatin was found in 21 (26%) duodenal and 21 (4%) pancreatic NETs. They were classified as sporadic (n=31) or neurofibromatosis type 1 (NF1)-associated duodenal NETs (n=3), gangliocytic paragangliomas (GCPGs; n=6), or poorly differentiated neuroendocrine carcinomas (pd…

AdultMaleCancer Researchmedicine.medical_specialtyEndocrinology Diabetes and Metabolism610 Medicine & healthNeuroendocrine tumorsGastroenterologyParagangliomaEndocrinologyDuodenal NeoplasmsInternal medicine10049 Institute of Pathology and Molecular PathologySomatostatinomaMultiple Endocrine Neoplasia Type 1MedicineHumansMEN11306 Cancer ResearchGenetic Predisposition to DiseaseNeurofibromatosisMultiple endocrine neoplasia610 Medicine & healthAgedAged 80 and overbusiness.industryIncidenceSyndromeSomatostatinomaMiddle Agedmedicine.diseasePrognosis1310 EndocrinologyPancreatic Neoplasms2712 Endocrinology Diabetes and MetabolismNeuroendocrine Tumorsmedicine.anatomical_structureSomatostatinOncologyDuodenum570 Life sciences; biology2730 OncologyFemalebusinessPancreasSomatostatinFollow-Up Studies
researchProduct